[{"id":"bd0915a0-fd20-4277-b54e-97bf1a6410c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03452774","created_at":"2021-01-18T17:01:36.578Z","updated_at":"2024-07-02T16:35:14.464Z","phase":"","brief_title":"SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry","source_id_and_acronym":"NCT03452774","lead_sponsor":"Massive Bio, Inc.","biomarkers":" EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703","pipe":" | ","alterations":" HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation","tags":["EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 50000","initiation":"Initiation: 01/01/2018","start_date":" 01/01/2018","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-03-15"},{"id":"bac1b09e-9082-44c7-ba9d-455e8eda253a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01510405","created_at":"2021-01-18T06:20:51.413Z","updated_at":"2024-07-02T16:35:41.477Z","phase":"","brief_title":"Phosphoproteomic Patterns as a Novel Biomarker for Aurora and Polo-like Kinase Inhibitors in Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT01510405","lead_sponsor":"Dartmouth-Hitchcock Medical Center","biomarkers":" AURKA • PLK1","pipe":"","alterations":" ","tags":["AURKA • PLK1"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 07/01/2010","start_date":" 07/01/2010","primary_txt":" Primary completion: 04/01/2020","primary_completion_date":" 04/01/2020","study_txt":" Completion: 04/01/2020","study_completion_date":" 04/01/2020","last_update_posted":"2023-08-01"},{"id":"ef3dd037-0458-48e4-a78e-804144c632c4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01601535","created_at":"2021-01-18T06:50:55.923Z","updated_at":"2024-07-02T16:36:57.512Z","phase":"Phase 1/2","brief_title":"Study of MLN8237 in Combination With Irinotecan and Temozolomide","source_id_and_acronym":"NCT01601535","lead_sponsor":"New Approaches to Neuroblastoma Therapy Consortium","biomarkers":" UGT1A1 • AURKA","pipe":" | ","alterations":" UGT1A1*1*1","tags":["UGT1A1 • AURKA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • irinotecan • alisertib (MLN8237)"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 05/01/2012","start_date":" 05/01/2012","primary_txt":" Primary completion: 07/25/2018","primary_completion_date":" 07/25/2018","study_txt":" Completion: 07/25/2018","study_completion_date":" 07/25/2018","last_update_posted":"2019-07-31"},{"id":"8defb032-2019-4105-9185-f94f7249e01c","acronym":"","url":"https://clinicaltrials.gov/study/NCT00697346","created_at":"2021-01-18T02:36:25.810Z","updated_at":"2024-07-02T16:36:59.184Z","phase":"Phase 1","brief_title":"Study of MLN8237 in Participants With Advanced Hematological Malignancies","source_id_and_acronym":"NCT00697346","lead_sponsor":"Millennium Pharmaceuticals, Inc.","biomarkers":" UGT1A1 • AURKA","pipe":" | ","alterations":" UGT1A1*1*1","tags":["UGT1A1 • AURKA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e alisertib (MLN8237)"],"overall_status":"Completed","enrollment":" Enrollment 58","initiation":"Initiation: 07/11/2008","start_date":" 07/11/2008","primary_txt":" Primary completion: 10/01/2016","primary_completion_date":" 10/01/2016","study_txt":" Completion: 10/19/2016","study_completion_date":" 10/19/2016","last_update_posted":"2019-05-31"},{"id":"3b0a3f00-fc96-4fd8-b90d-f41daa3423e3","acronym":"","url":"https://clinicaltrials.gov/study/NCT01779843","created_at":"2021-01-18T07:50:50.749Z","updated_at":"2024-07-02T16:37:25.597Z","phase":"Phase 1","brief_title":"Alisertib for Acute Myeloid Leukemia","source_id_and_acronym":"NCT01779843","lead_sponsor":"Massachusetts General Hospital","biomarkers":" AURKA","pipe":"","alterations":" ","tags":["AURKA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • idarubicin hydrochloride • alisertib (MLN8237)"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 04/01/2013","start_date":" 04/01/2013","primary_txt":" Primary completion: 11/01/2015","primary_completion_date":" 11/01/2015","study_txt":" Completion: 11/01/2016","study_completion_date":" 11/01/2016","last_update_posted":"2017-02-17"}]